Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 4/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ACP1 | P24666 | 1/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | LATS1 | O95835 | 1/20 | 0.34 |
| ▸ | LATS2 | Q9NRM7 | 1/20 | 0.34 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | IDH1 | O75874 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13914459 | 0.81 | KDM4E (0.36) | TLR8TLR7KDM4EPRMT5MAPT | |
| SCHEMBL3868731 | 0.80 | TLR7 (0.38) | TLR8TLR7KDM4EACP1PRMT5 | |
| SCHEMBL31197374 | 0.79 | ACP1 (0.47) | TLR7KDM4EACP1GAAMAPT | |
| SCHEMBL4725461 | 0.79 | ACP1 (0.47) | TLR7KDM4EACP1GAAMAPT | |
| SCHEMBL31197376 | 0.79 | ACP1 (0.47) | TLR7KDM4EACP1GAAMAPT | |
| Hydrochloric Acid SCHEMBL5442383 | 0.78 | ACP1 (0.46) | TLR7KDM4EACP1GAAMAPT | |
| SCHEMBL6387545 | 0.78 | GBA1 (0.43) | TLR8TLR7KDM4EGAAMAPT | |
| SCHEMBL3355697 | 0.78 | TLR8 (0.36) | TLR8TLR7KDM4EPRMT5EGFR | |
| SCHEMBL191477 | 0.78 | MAPT (0.48) | KDM4EGAAMAPTALDH1A1CYP1A2 | |
| SCHEMBL8133953 | 0.77 | TLR8 (0.41) | TLR8TLR7KDM4EPRMT5MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1833827-B9 | PROCESS FOR PREPARING 2-METHYL-1-(2-METHYLPROPYL)-1H-IMIDAZO[4,5-C][1,5]NAPHTHYRIDIN-4-AMINE | MEDA AB (SE) | 2012-01-04 | — | — | EP | claimed |
| EP-1833827-B1 | PROCESS FOR PREPARING 2-METHYL-1-(2-METHYLPROPYL)-1H-IMIDAZO[4,5-C][1,5]NAPHTHYRIDIN-4-AMINE | MEDA AB (SE) | 2011-05-25 | — | — | EP | claimed |
| US-20080306266-A1 | Process for Preparing 2-Methyl-1-(2-Methylpropyl)-1H-Imidazo[4,5-C][1,5]Naphthyridin-4-Amine | 3M INNOVATIVE PROPERTIES COMPANY | 2008-12-11 | — | — | US | claimed |
| US-8436176-B2 | Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine | MEDICIS PHARMACEUTICAL CORPORATION (US) | 2013-05-07 | — | — | US | disclosed |
| EP-1833827-B9 | PROCESS FOR PREPARING 2-METHYL-1-(2-METHYLPROPYL)-1H-IMIDAZO[4,5-C][1,5]NAPHTHYRIDIN-4-AMINE | MEDA AB (SE) | 2012-01-04 | — | — | EP | disclosed |
| EP-1833827-B1 | PROCESS FOR PREPARING 2-METHYL-1-(2-METHYLPROPYL)-1H-IMIDAZO[4,5-C][1,5]NAPHTHYRIDIN-4-AMINE | MEDA AB (SE) | 2011-05-25 | — | — | EP | disclosed |
| US-20090124652-A1 | Polymorphs of 1-(2-Methylpropyl)-1H-Imidazo[4,5-C][1,5]Naphthyridin-4-Amine Ethane-Sulfonate | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-05-14 | — | — | US | disclosed |
| US-20090124652-A1 | Polymorphs of 1-(2-Methylpropyl)-1H-Imidazo[4,5-C][1,5]Naphthyridin-4-Amine Ethane-Sulfonate | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-05-14 | — | — | US | disclosed |
| US-20080306266-A1 | Process for Preparing 2-Methyl-1-(2-Methylpropyl)-1H-Imidazo[4,5-C][1,5]Naphthyridin-4-Amine | 3M INNOVATIVE PROPERTIES COMPANY | 2008-12-11 | — | — | US | disclosed |
| US-20080306266-A1 | Process for Preparing 2-Methyl-1-(2-Methylpropyl)-1H-Imidazo[4,5-C][1,5]Naphthyridin-4-Amine | 3M INNOVATIVE PROPERTIES COMPANY | 2008-12-11 | — | — | US | disclosed |
| US-20080188513-A1 | 1-(2-Methylpropyl)-1H-Imidazo[4,5-C](1,5]Naphthyridin-4-Amine Ethanesulfonate and 1-(2-Methylpropyl)-1H-Imidazo[4,5-C](1,5]Naphthyridin-4-Amine Methanesulfonate | TAKED PHARMACEUTICAL COMPANY LIMITED | 2008-08-07 | — | — | US | disclosed |
| US-20080188513-A1 | 1-(2-Methylpropyl)-1H-Imidazo[4,5-C](1,5]Naphthyridin-4-Amine Ethanesulfonate and 1-(2-Methylpropyl)-1H-Imidazo[4,5-C](1,5]Naphthyridin-4-Amine Methanesulfonate | TAKED PHARMACEUTICAL COMPANY LIMITED | 2008-08-07 | — | — | US | disclosed |
| US-6638944-B2 | Have urea containing substituent at 1-position; induce biosynthesis of cytokines such as interferon and tumor necrosis factor, exhibit antiviral and antitumor properties | 3M INNOVATIVE PROPERTIES COMPANY | 2003-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188513-A1 | 1-(2-Methylpropyl)-1H-Imidazo[4,5-C](1,5]Naphthyridin-4-Amine Ethanesulfonate and 1-(2-Methylpropyl)-1H-Imidazo[4,5-C](1,5]Naphthyridin-4-Amine Methanesulfonate | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NDC1, CLIC1 | TLR8 1489/4885TLR7 1147/4885KDM4E 1227/4885 |
| US-20090124652-A1 | Polymorphs of 1-(2-Methylpropyl)-1H-Imidazo[4,5-C][1,5]Naphthyridin-4-Amine Ethane-Sulfonate | CYP2S1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP2D6 | TLR8 3533/4885TLR7 1854/4885KDM4E 2290/4885 |
| US-20080306266-A1 | Process for Preparing 2-Methyl-1-(2-Methylpropyl)-1H-Imidazo[4,5-C][1,5]Naphthyridin-4-Amine | DNMT1, NT5C, JMJD1C | TLR8 1020/4885TLR7 570/4885KDM4E 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.